<DOC>
	<DOCNO>NCT01426412</DOCNO>
	<brief_summary>This study otherwise healthy Japanese non-Japanese participant elevate low density lipoprotein cholesterol ( LDL-C ) . Following single dos LY3015014 , safety tolerability drug , body handle drug , drug 's effect body evaluate . Participants remain study approximately 6 month .</brief_summary>
	<brief_title>A Study LY3015014 Healthy Participants With Elevated Low Density Lipoprotein Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination To qualify Japanese purpose study , participant must firstgeneration Japanese , define participant 's biological parent participant 's biological grandparent must exclusive Japanese descent , must bear Japan . Japanese participant age 2065 , inclusive , screen Statin naive participant , screen LDLC 100 180 milligram per deciliter ( mg/dL ) , inclusive ; participant currently take statin , screen LDLC 100 160 mg/dL Have serum triglyceride &lt; 400 mg/dL Additional inclusion criterion participant statininteraction cohort : At screening , must stable dose either atorvastatin ( 10 40 mg daily [ QD ] ) , rosuvastatin ( 5 20 mg QD ) , simvastatin ( 20 40 mg QD ) , lovastatin ( 40 80 mg QD ) , pravastatin ( 40 80 mg QD ) well tolerate least 3 month Have know allergy compound related LY3015014 component formulation , know clinically significant hypersensitivity biologic agent , know allergy acetaminophen and/or antihistamine Intend use overthecounter prescription medication within 14 day prior dose ( exclude statin list Inclusion Criterion estrogen/progesterone hormone replacement therapy ( HRT ) thyroid medication . Participants take medication chronic , stable dos . Certain medication , example vitamin supplement , may permit discretion investigator sponsor . Participants statins may allow stable dose single hypertensive agent agree upon sponsor investigator Have receive vaccine ( ) within 1 month LY3015014 dosing , intend study Have receive treatment biologic agent ( monoclonal antibody ) within 3 month 5 halflives ( whichever longer ) prior dose Have history atopy , significant allergy humanize monoclonal antibody , clinically significant multiple severe drug allergy , intolerance topical corticosteroid , severe posttreatment hypersensitivity reaction ( include , limited , erythema multiforme major , linear immunoglobulin ( Ig ) A dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) Additional exclusion criterion participant statininteraction cohort : Incidence unexplained muscle pain , incidence frequent muscle cramp within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>